NEWS & EVENTS

Moderna and Catalent today announced the expansion of their strategic partnership to dedicate a new high-speed vial filling line for the manufacture of the Moderna COVID-19 Vaccine at Catalent’s facility in Bloomington, Indiana.

Catalent has signed an agreement with Cybin Inc to apply Catalent’s proprietary Zydis® orally disintegrating tablet (ODT) technology for the delivery of Cybin’s novel deuterated tryptamine (CYB003), a potential therapy for treatment-resistant psychiatric disorders.

Catalent today announced Catalent Biologics will significantly increase the manufacturing capacity for large-scale commercial supply of Janssen’s COVID-19 vaccine at Catalent’s manufacturing facility in Anagni, Italy.

As a development and manufacturing partner that supplies medicines, clinical trial materials, and health products to patients and consumers, we are taking action to minimize the impact of the COVID-19 pandemic.

Catalent today announced that two of its clinical supply experts will be participating in upcoming digital events, Clinical Trial Supply Europe and Clinical Trial Supply Roundtable Forum 2021.

EuropaBio today announced that Catalent has joined EuropaBio’s 25th Anniversary Celebration Programme as a major sponsor.

Together, the addition of pDNA technology and production capabilities marks a significant milestone for Catalent Cell & Gene Therapy.

Catalent today announced that it recently signed a multi-year commercial supply agreement with Aurinia Pharmaceuticals, for LUPKYNIS™ (voclosporin), a drug to treat adult patients with lupus nephritis (LN).

Catalent has completed the acquisition of the manufacturing and packaging operations of Acorda Therapeutics, Inc., a developer of therapies to restore function and improve the lives of people with neurological disorders.